Open beta · everything is free with an account while we build. Founding accounts get preferred pricing when paid plans arrive. Create yours →

AVIVA STRATEGIES (FKA MGB CONSULTING)

Washington, DC
Registered · LDAActive
Request introduction →Claim this firm →

At a glance

Clients
8
past 12 months
Professionals
1
on past-year filings
Filings
10
past 12 months
Activity
filings by quarter
What this firm works onclick an issue to see who works it
Health Issues 7Medical/Disease Research/Clinical Labs 1
Typical engagement · past 12 months
$██-██,███ / qtrFree in beta

Team

MB
MAX BRONSTEIN
Government relations professional
7 filings

Client roster

ARPA-H GO
2026 · 2 filings
$██,███ / qtrFree in beta
ULTRAGENYX PHARMACEUTICAL
2026 · 1 filing · engagement ended
$██,███ / qtrFree in beta
ACT FOR ULTRA RARE
2026 · 2 filings
$██,███ / qtrFree in beta
TAYSHA GENE THERAPIES
2026 · 1 filing
$██,███ / qtrFree in beta
BEAM THERAPEUTICS
2026 · 1 filing
$██,███ / qtrFree in beta
HUNTINGTON'S DISEASE SOCIETY OF AMERICA
2026 · 1 filing
$██,███ / qtrFree in beta
ELEMENT BIOSCIENCES
2026 · 1 filing
$██,███ / qtrFree in beta
ENDEAVOR BIOMEDICINES
2026 · 1 filing
$██,███ / qtrFree in beta

Sources

This profile is built from the public record: filings in the U.S. Senate Lobbying Disclosure Act system. lda.senate.gov ↗

Recent filings10
2026 Q1
ARPA-H GO
Q1lda.gov →
2026 Q1
ARPA-H GO
RRlda.gov →
2026 Q1
ULTRAGENYX PHARMACEUTICAL
1Tlda.gov →
2026 Q1
ACT FOR ULTRA RARE
Q1lda.gov →
2026 Q1
TAYSHA GENE THERAPIES
Q1Ylda.gov →
2026 Q1
BEAM THERAPEUTICS
Q1Ylda.gov →
2026 Q1
HUNTINGTON'S DISEASE SOCIETY OF AMERICA
Q1Ylda.gov →
2026 Q1
ELEMENT BIOSCIENCES
Q1lda.gov →
2026 Q1
ACT FOR ULTRA RARE
RRlda.gov →
2026 Q1
ENDEAVOR BIOMEDICINES
Q1lda.gov →